All posts tagged: leukaemia

Early forever chemicals exposure linked to higher lymphoblastic leukaemia risk in children

Early forever chemicals exposure linked to higher lymphoblastic leukaemia risk in children

Researchers at the University of California, Irvine, have identified a potential link between early-life exposure to PFAS, widely used industrial chemicals, and an increased risk of lymphoblastic leukaemia, the most common cancer in children. The study, published in the Journal of Exposure Science & Environmental Epidemiology, analysed newborn blood samples to directly measure chemical exposure at birth rather than relying on environmental estimates. The findings suggest that infants with higher levels of specific PFAS compounds in their blood may face elevated odds of developing lymphoblastic leukaemia, adding weight to concerns about how environmental toxins affect early childhood health. The research was supported by funding from the National Institutes of Health, highlighting growing institutional focus on the long-term health effects of environmental contaminants. Why are PFAS dangerous? Per- and polyfluoroalkyl substances (PFAS) are a large class of synthetic chemicals used in everyday products, including nonstick cookware, food packaging, waterproof fabrics and drinking water systems. Often referred to as “forever chemicals,” PFAS are highly persistent and accumulate in both the environment and the human body over time. …

Repurposed drugs could improve treatment for rare infant leukaemia

Repurposed drugs could improve treatment for rare infant leukaemia

A research team identified three genes connected to a rare form of childhood leukaemia and found that clinically available drugs had a positive influence on these genes in tests on mice, increasing rates of survival. KMT2A::AFF1 positive B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is a rare but severe form of infant leukaemia, caused by changes in the KMT2A::AFF1 gene. Characterised by rapid disease progression, a high risk of relapse and limited treatment options, BCP-ALL requires equally aggressive chemotherapy, although this can in turn cause serious side effects. BCP-ALL is also the most common genetic driver of leukaemia in infants, occurring in the majority of cases diagnosed in children aged one and under. Acetazolamide and tacrolimus could be alternatives to intense chemotherapy drugs However, research from the University of Edinburgh has shown promise for developing more effective treatments. In studies on mice, three microRNA molecules (miR-194, miR-99b and miR-125a-5p) that are found at unusually low levels in BCP-ALL sufferers, were restored and consequently displayed slowed growth and survival of cancer cells. Three genes linked to this …